U.S. NUCLEAR REGULATORY COMMISSION

MATERIALS LICENSE

Pursuant to the Atomic Energy Act of 1954, as amended, the Energy Reorganization Act of 1974 (Public Law 93-438), and Title 10, Code of Federal Regulations, Chapter I, Parts 30, 31, 32, 33, 34, 35, 36, 37, 39, 40, 70 and 71, and in reliance on statements and representations heretofore made by the licensee, a license is hereby issued authorizing the licensee to receive, acquire, possess, and transfer byproduct, source, and special nuclear material designated below; to use such material for the purpose(s) and at the place(s) designated below; to deliver or transfer such material to persons authorized to receive it in accordance with the regulations of the applicable Part(s). This license shall be deemed to contain the conditions specified in Section 183 of the Atomic Energy Act of 1954, as amended, and is subject to all applicable rules, regulations, and orders of the Nuclear Regulatory Commission now or hereafter in effect and to any conditions specified below.

	Licen	see		In accordance with letter dated		4. Expiration Date: November 30, 2023	
1.	Porter Regional Hospital		June 1	R REGULA	5 Dools	rot No. (020, 12150	
	85 E. U.S. Hwy 6 Valparaiso, IN 46383			ense number: 13-17073-01 is ended in its entirety to read as ows:		tet No.: 030-12150 rence No.:	
6.	Byproduct, source, and/or special nuclear material	7.	Chemical and/or physical form	Maximum amount that licens may possess at any one time under this license		Authorized use	
Α.	Any byproduct material permitted by 10 CFR 35.100	A.	Any O	A. As Needed	※ A.	For use in uptake, dilution and excretion studies permitted by 10 CFR 35.100.	
В.	Any byproduct material permitted by 10 CFR 35.200	B.	Any	B. As Needed	В.	For use in imaging and localization studies permitted by 10 CFR 35.200.	
C.	Any byproduct material permitted by 10 CFR 35.300	C.	Any	C. 2 curies total	C.	For any use permitted by 10 CFR 35.300.	
D.	Iridium-192 permitted by 10 CFR 35.400	D.	Sealed Sources (Best Medical International, Inc., Model 81-01)	D. 2 curies total	D.	For any manual brachytherapy procedure permitted by 10 CFR 35.400	
Ε.	lodine-125 permitted by 10 CFR 35.400	E.	Sealed Sources (Bard Brachytherapy, Inc, Model STM 1251)	E. 2 curies total	E.	For any manual brachytherapy procedure permitted by 10 CFR 35.400	

NRC	FORM	I 374A	U.S. NUCLEAR RI	EGULATORY COMMI	SSION	PAGE 2 OF 4 PAGES		
	MAIERIALS LICENSE		License Number 13-17073-01		Docket or Reference Nur 030-12150	nber		
			Amendment No. 51					
					<u></u>			
6.		or special nuclear		may possess a	ount that licensee 9. at any one time	Authorized use		
F.	Yttri	ium-90 permitted by F. Microspheres CFR 35.1000 Technology 0		F. 2 curies total		For medical use as permitted by 10 CFR 35.1000 in a Sirtex Medical Limited brachytherapy afterloader delivery system.		
					T)			
10.	CONDITIONS 10. A. Licensed material may be used or stored at the licensee's facilities located at 85 E. U.S. Hwy 6, Valparaiso, Indiana 46383.							
		Licensed material in Subitem Nos. 6.4 Chesterton, Indiana 46304 and at Por 46383.	A. and 6.B. may be used	or stored at the	licensee's facilities le Physician Group, 20	ocated at 1505 S. Calumet,		
11.	The	e Radiation Safety Officer (RSO) for thi	s license is James M. F	orde, M.D.				
12.	Lic	ensed material shall only be used by, o	or under the supervision	of:	40,			
	A. Individuals permitted to work as authorized users in accordance with 10 CFR 35.13 and 10 CFR 35.14.							
	B.	The following individuals are authorized	ed users for the material	and medical us	es as indicated:			
		Authorized User(M.D.,D.O.,etc.)	Material and Use					
		Amjad Alkadri, M.D.	10 CFR 35.100,10 C SIR-Spheres)	FR 35.200,10 C	FR 35.300,10 CFR 3	5.1000 (limited to yttrium-90 as		
		Keith Atassi, M.D.	10 CFR 35.200					

FORM 374A	U.S. NUCLEAR REGULATO	RY COMMISSION PAGE 3 OF 4 PAGES
MATERIALS LICENSE	License Number 13-17073-01	Docket or Reference Number 030-12150
SUPPLEMENTARY SHEET	Amendment No. 51	
Authorized User(M.D.,D.O.,etc.)	Material and Use	
Omar Barakat, M.D.	iodide I-131 and the parente	200,10 CFR 35.300 (limited to the oral administration of sodium ral administration of any beta-emitter, or photon-emitting nergy less than 150 keV),10 CFR 35.1000 (limited to yttrium-90 as
Maximo V. Bleza, D.O.	10 CFR 35.100,10 CFR 35.2	200,10 CFR 35,300
John A. Forchetti, M.D.	10 CFR 35.100,10 CFR 35.2	200
James M. Forde, M.D.	10 CFR 35.100,10 CFR 35.2	200,10 CFR 35.300
Steven L. Hossler, M.D.	10 CFR 35 100,10 CFR 35.2	200
Jeffrey M. Huth, M.D.	10 CFR 35:100,10 CFR 35:2	
Akram Kholoki, M.D.	10 CFR 35.100 10 CFR 35.2	200
Anil Kothari, M.D.	iodide I-131 in quantities les	200,10 CFR 35.300 (limited to the oral administration of sodium s than or equal to 33 millicuries)
Esther Lee, M.D.	10 CFR 35.100 10 CFR 85. iodide I-131)	200,10 CFR 35.300 (limited to the oral administration of sodium
Hector J. Marchand, M.D.	10 CFR 35.200	5
Vivek Mishra, M.D.	iodide 1.131 and the parente	200,10 CFR 35,300 (limited to the oral administration of sodium eral administration of any beta-emitter, or photon-emitting energy less than 150 keV),10 CFR 35.1000 (limited to yttrium-90 as
Jeffrey Jon Quackenbush, M.D.	10 CFR 35.300,10 CFR 35.	400
Koppolu P. Sarma, M.D.	10 CFR 35.400	
Sandeep Sehgal, M.D.	10 CFR 35.200	
Jay D. Shah, M.D.	10 CFR 35.100,10 CFR 35.	200
Michael Wheat, M.D.	10 CFR 35.200	

MATERIALS LICENSE SUPPLEMENTARY SHEET License Number 13-17073-01 Docket or Reference Number 030-12150	DACEC
MATERIALS LICENSE SUPPLEMENTARY SHEET 13-17073-01 Amendment No. 51 13-17073-01 Amendment No. 51	PAGES
13. Except as specifically provided otherwise in this license, the licensee shall conduct its program in accordance with the statements, representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies or those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not lim licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations. A. Application dated June 21, 2013 (ML13183A468)	
representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies or those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations. A. Application dated June 21, 2013 (ML13183A468)	
representations, and procedures contained in the documents, including any enclosures, listed below. This license condition applies or those procedures that are required to be submitted in accordance with the regulations. Additionally, this license condition does not limit licensee's ability to make changes to the radiation protection program as provided for in 10 CFR 35.26. The U.S. Nuclear Regulatory Commission's regulations shall govern unless the statements, representations, and procedures in the licensee's application and correspondence are more restrictive than the regulations. A. Application dated June 21, 2013 (ML13183A468)	
B. Letter dated August 4, 2015 (ML15224B609) C. Letter dated September 22, 2017 (ML17268A220) D. Letter dated June 12, 2018 (ML18166A327) FOR THE U.S. NUCLEAR REGULATORY COMMISSION	limit the
Date: SEP 1 1 2018 By: Bryan A. Parker Region III	